Intravenous Ketorolac (Toradol) Dosing for Adults
For adults under 65 years with normal renal function and body weight ≥50 kg, administer 30 mg IV ketorolac over at least 15 seconds every 6 hours, not exceeding 120 mg daily for a maximum of 5 days. 1
Standard Dosing by Patient Population
Adults <65 Years, Normal Renal Function, ≥50 kg
Single-dose treatment:
- 30 mg IV given over no less than 15 seconds 1
Multiple-dose treatment:
- 30 mg IV every 6 hours
- Maximum daily dose: 120 mg
- Maximum duration: 5 days (combined IV and oral) 1
High-Risk Populations (≥65 years, renal impairment, or <50 kg)
Single-dose treatment:
- 15 mg IV given over no less than 15 seconds 1
Multiple-dose treatment:
- 15 mg IV every 6 hours
- Maximum daily dose: 60 mg
- Maximum duration: 5 days 1
The FDA label explicitly defines these weight-based and age-based adjustments, which are critical for safety 1. The 50% dose reduction in elderly and renally impaired patients reflects the increased half-life (5 hours in young adults versus 7 hours in elderly) and altered pharmacokinetics in these populations 1.
Renal Impairment Considerations
Ketorolac should be used with extreme caution in patients with any degree of renal impairment. The NCCN guidelines recommend short-term use of ketorolac at 15-30 mg IV for a maximum of 5 days 2. However, this must be balanced against significant renal toxicity risks.
Critical contraindications and warnings:
- Patients with creatinine clearance <30 mL/min should generally avoid ketorolac
- Correct hypovolemia before administration 1
- Discontinue if BUN or creatinine doubles 2
- Patients with chronic kidney disease receiving ketorolac in local infiltration showed 12.7% AKI incidence versus 2.0% without ketorolac 3
The evidence strongly suggests that in patients with pre-existing CKD, even the reduced 15 mg dose carries substantial risk. A 2025 study demonstrated a 6-fold increase in AKI risk when ketorolac was used in CKD patients 3.
Administration Technique
IV bolus must be given over no less than 15 seconds 1. This is a specific FDA requirement to minimize adverse effects. The analgesic effect begins in approximately 30 minutes with maximum effect at 1-2 hours, lasting 4-6 hours 1.
Duration Limits
The combined duration of IV and oral ketorolac must not exceed 5 days in adults 1. This is an absolute limit, not a guideline. The NCCN cancer pain guidelines specifically state "short-term use of ketorolac; 15-30 mg IV, every times day for maximum of 5 days" 2.
Clinical Efficacy Evidence
Recent research demonstrates that lower doses may be equally effective. A 2023 systematic review found that 10-20 mg ketorolac provides similar pain relief to 30 mg doses (mean difference 0.05 mm on 100 mm VAS, 95% CI -4.91 to +5.01) 4. A 2021 trial in renal colic showed no significant difference between 10 mg, 20 mg, and 30 mg doses 5.
However, the FDA-approved dosing remains the standard of care 1. While lower doses may be effective, they may require more rescue analgesia 4, and the 30 mg dose for standard patients and 15 mg for high-risk patients represents the established safety and efficacy profile.
High-Risk Populations Requiring Avoidance or Extreme Caution
Absolute avoidance:
- Age >60 years with compromised fluid status
- Active peptic ulcer disease or GI hemorrhage
- Bleeding disorders or thrombocytopenia
- Concurrent anticoagulation (warfarin, heparin)
- Severe renal impairment (CrCl <30 mL/min)
- Pregnancy 2
Use with extreme caution and monitoring:
- Cardiovascular disease or risk factors
- Concurrent nephrotoxic drugs (cyclosporine, cisplatin)
- Hepatic dysfunction
- History of peptic ulcer disease
- Significant alcohol use (≥2 drinks daily) 2
Monitoring Requirements
When using ketorolac, obtain baseline and monitor:
- Blood pressure
- BUN and creatinine
- Liver function tests (alkaline phosphatase, LDH, SGOT, SGPT)
- CBC and fecal occult blood
- Repeat every 3 months if prolonged use (though duration should not exceed 5 days) 2
Discontinue immediately if:
- BUN or creatinine doubles
- Hypertension develops or worsens
- Liver function tests increase >3 times upper limit of normal
- Peptic ulcer or GI hemorrhage occurs 2
Practical Algorithm for Dosing Decision
Assess patient eligibility: Rule out absolute contraindications (active GI bleeding, severe renal impairment, pregnancy, bleeding disorders)
Determine risk category:
- Standard risk: Age <65, weight ≥50 kg, normal renal function → 30 mg IV
- High risk: Age ≥65, weight <50 kg, OR any renal impairment → 15 mg IV
Correct hypovolemia before administration 1
Administer over ≥15 seconds 1
Repeat dosing: Every 6 hours as needed, not exceeding daily maximum (120 mg standard, 60 mg high-risk)
Plan transition: Switch to alternative analgesics as soon as possible; never exceed 5 days total duration 1
Monitor: If any signs of renal, GI, or cardiac toxicity develop, discontinue immediately